Sigma-Aldrich Signs Distribution Agreement With AlphaGenix
Posted on: Friday, 14 November 2008, 12:00 CST
Sigma-Aldrich, a life science and high technology company, has signed a distribution agreement with AlphaGenix, a developer and manufacturer of products for basic and clinical life science research.
Pursuant to the terms of the agreement, Sigma-Aldrich will now be the exclusive supplier of AlphaGenix-developed antibodies and research tools for the fields of regenerative medicine and stem cell biology. This partnership is expected to further augment Sigma-Aldrich's product portfolio of life science tools for stem cell research.
The new product offerings include antibodies to stem cell markers; tools for 3-D stem cell culture systems, such as MaxGel, a human derived extracellular matrix and its components; and HydroMatrix, a synthetic peptide scaffold that offers the precision and control of a synthesized matrix with the natural 3-D architecture of a highly crosslinked peptide hydrogel.
Both MaxGel and HydroMatrix promote cell growth and migration and have been shown to support the proliferation and enhance function of many cell types, including neural stem cells, neurons, glia, astrocytes, fibroblasts, and keratinocytes, the two companies said.
Carl Schrott, director of marketing for regenerative medicine and research cell culture at Sigma-Aldrich, said: "It is increasingly important to design cell culture assays that closely mimic the behavior of cells in living tissues. Through this partnership, we will offer our customers new tools to grow stem cells that resemble their in vivo counterparts, and the high-quality antibodies needed to study them."
Source: Datamonitor
Related Articles
- Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68
- Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM)
- Sigma-Aldrich Announces Addition of 2,000 New Antibodies
- Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
- Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
- Sigma-Aldrich Announces Collaboration With Metahelix Life Sciences
- Sigma-Aldrich Announces Launch of a New Antibodies Catalog
- Sigma-Aldrich Board Member Nina Fedoroff Resigns to Become Science and Technology Adviser to U.S. Secretary of State
- Sigma-Aldrich Releases New 2006 Cell Signaling & Neuroscience Catalog Supplement
- Sigma-Aldrich Launches GenomePlex(R) Single Cell Whole Genome Amplification (WGA) Kit
User Comments (0)

RSS Feeds